Actively Recruiting
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-14
10
Participants Needed
1
Research Sites
512 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
CONDITIONS
Official Title
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients planned to receive stereotactic body radiotherapy (SBRT) for biopsy-proven or suspected non-small cell lung cancer
- Age over 18 years
- Patient capable of giving informed consent
- Patients planned to receive precision hypofractionated radiation (SBRT or ablative dose if SBRT not suitable) to all sites of oligoprogressive NSCLC after first line systemic therapy including immunotherapy or tyrosine kinase inhibitors
- Fewer than 5 sites of progression
- Patient capable of giving informed consent
You will not qualify if you...
- Use of antibiotics, antifungal, antivirals, or antiparasitics during the 4 weeks prior to registration
- Active infection with oral temperature over 100°F
- Use of corticosteroids, methotrexate, or immunosuppressive drugs during the 4 weeks prior to registration
- Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy, with chemotherapy not allowed before collection of 30-day post-treatment sample
- Documented history of HIV, HBV, or HCV
- Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate or severe irritable bowel syndrome, persistent infectious gastroenteritis, colitis, gastritis, persistent or chronic diarrhea of unknown cause, recent Clostridium Difficile infection, or untreated Helicobacter Pylori infection
- Major gastrointestinal surgery (except cholecystectomy and appendectomy) within past five years or any major bowel resection
- Use of anti-diarrheal medications
- Use of probiotics
- Evidence of untreated central nervous system or leptomeningeal disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
C
Ching Lai
CONTACT
R
RadOnc Clinical Research Unit
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here